Related Experiment Video
Updated: May 2, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.0K
Rituximab used in three cases with relapsed non-Hodgkin's lymphoma
Murat Elli1, Sema Yilmaz1, Ramazan Aydin2
1Departments of Pediatric Hematology/Oncology, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey.
Molecular and Clinical Oncology
|March 21, 2014
Summary
This study shows that combining rituximab with chemotherapy effectively treats relapsed B-cell non-Hodgkin
Area of Science:
- Pediatric Oncology
- Hematology
- Immunotherapy
Background:
- Relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) in children carries a poor prognosis.
- CD20 is a highly expressed target (>98%) in childhood B-NHL.
- Rituximab, an anti-CD20 monoclonal antibody, is a potential therapeutic option for relapsed B-NHL.
Purpose of the Study:
- To evaluate the efficacy of rituximab in combination with chemotherapy for pediatric B-NHL.
- To assess treatment outcomes in children with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Main Methods:
- Retrospective analysis of three pediatric B-NHL cases.
- Treatment involved an intensive chemotherapy protocol combined with rituximab.
- Focus on patients with relapsed or refractory disease.
Main Results:
- All three cases of relapsed B-NHL achieved successful treatment outcomes.
- The combination therapy demonstrated positive results in this small cohort.
Conclusions:
- Combination of intensive chemotherapy and rituximab is an effective treatment strategy for relapsed B-NHL in children.
- Rituximab shows promise as a component of salvage therapy for pediatric B-cell non-Hodgkin's lymphoma.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K